-
Difloxacin HCl: Reliable Cell Assay Workflows
2026-09-05
This scenario-driven guide explains how Difloxacin HCl (SKU A8411) can support antimicrobial susceptibility testing and multidrug-resistance studies while protecting cell-viability data from avoidable preparation and interpretation errors. It connects formulation details, assay controls, and mechanistic evidence to practical laboratory decisions.
-
ACE Inhibitor-Mediated Angioedema: Mechanisms and Care
2026-09-04
This review synthesizes the epidemiology, bradykinin-centered pathophysiology, clinical presentation, genetic susceptibility, and management challenges of ACE inhibitor-mediated angioedema. Its practical contribution is to distinguish this acquired, non-histaminergic reaction from conventional allergic angioedema while clarifying the uncertainty surrounding icatibant, fresh frozen plasma, C1 inhibitor therapy, and switching to an angiotensin-receptor blocker.
-
Co-targeting BRD4 and RAC1 in Breast Cancer
2026-09-04
The reference study identifies combined BRD4 and RAC1 inhibition as a subtype-aware strategy that suppresses breast cancer growth, migration, stemness, and tumorigenesis. Its mechanistic contribution is to connect this combination with disruption of the c-MYC–G9a–FTH1 axis and downregulation of HDAC1, providing a framework for evaluating coordinated signaling and chromatin regulation.
-
Cy5 amine (non-sulfonated): Labeling Guide
2026-09-04
Cy5 amine (non-sulfonated) provides a primary amino handle for covalent fluorescent labeling of compatible proteins, peptides, polymers, and related biomolecular targets. Because it is insoluble in water, it should be dissolved in DMSO or ethanol before transfer into an aqueous labeling workflow and should not be used for direct aqueous, diagnostic, or medical applications.
-
FHND004 Targets PBK in Multiple Myeloma
2026-09-03
The reference study identifies PDZ-binding kinase (PBK) as a previously underdeveloped target of FHND004 in multiple myeloma and connects this activity to ERK1/2 signaling within the MAPK pathway. Its combination of cell assays, transcriptomics, protein screening, binding validation, and in vivo models provides a preclinical framework for evaluating EGFR-derived compounds beyond canonical EGFR inhibition.
-
AZ505: Selective SMYD2 Inhibitor Workflow
2026-09-02
A scenario-based guide to using AZ505, a potent and selective SMYD2 inhibitor, in cell viability, proliferation, and cytotoxicity workflows. It explains how SKU B1255 links biochemical potency with practical controls, model selection, data interpretation, and vendor reliability.
-
Dual Luciferase Reporter Gene System for Al Stress
2026-09-02
Learn how a Dual Luciferase Reporter Gene System can convert the tomato SlSTOP1–SlSLAH1 aluminium-tolerance mechanism into a rigorous promoter-testing strategy. This article emphasizes reporter architecture, normalization limits, and the practical boundaries of applying mammalian-cell reagents to plant regulatory biology.
-
Ganetespib (STA-9090) Workflow for Hsp90 Studies
2026-09-01
Ganetespib (STA-9090) combines a non-geldanamycin scaffold with potent Hsp90 inhibition, making it useful for connecting client-protein destabilization to cancer-cell phenotypes. This guide translates that mechanism into practical dose-response, target-engagement, release-assay, and troubleshooting workflows while clearly separating oncology evidence from a recent virology insight.
-
Z-DEVD-FMK: Caspase-3 Inhibitor Workflows
2026-09-01
Z-DEVD-FMK enables controlled dissection of apoptosis, caspase signaling, and calpain-linked proteolysis in cell and neurobiology models. Its use in SADS-CoV research also shows how a caspase-3 inhibitor can connect programmed cell death with antiviral innate-immunity assays.
-
Rimonabant (SR141716) for CB1 Mechanism Studies
2026-08-31
Rimonabant (SR141716) gives researchers a selective CB1 blockade tool for separating cannabinoid-dependent signaling from appetite, inflammatory, and pain-related phenotypes. Its strongest use is as a mechanistic comparator in carefully controlled cell, feeding, and neuropathic-pain workflows—not as a substitute for pathway-specific validation.
-
LGK-974: A Practical PORCN Inhibitor Workflow
2026-08-31
A practical guide to using LGK-974 as a PORCN inhibitor for Wnt-dependent cancer models and mechanistic bone research. The workflow connects nanomolar pathway control with target-engagement readouts, dose optimization, and troubleshooting for reproducible experiments.
-
Oseltamivir acid for Reliable Cell Assays
2026-08-30
Oseltamivir acid (SKU A3689) offers a practical way to standardize neuraminidase-inhibition studies, stock preparation, and viability or cytotoxicity workflows. This scenario-based guide connects product specifications with influenza antiviral research, resistance-aware interpretation, and carefully bounded oncology applications.
-
4-Ethylphenyl Sulfate: Assay Design Guide
2026-08-29
Explore how 4-ethylphenyl sulfate connects renal toxin profiling with gut microbiota-brain interaction research. This evidence-based guide translates adsorption findings, chemical specifications, and preclinical neurobehavioral data into practical assay decisions.
-
MK-5108: AURKA Evidence in Retinoblastoma
2026-08-28
MK-5108 (VX-689) is a highly selective Aurora A inhibitor for testing mitotic dependence in cancer models. This article connects retinoblastoma biology with evidence-driven assay selection, model validation, and xenograft interpretation.
-
Substrate Stiffness and LAMB1–FAK–MEK1/2 Dentinogenesis
2026-08-28
The reference study shows that substrate stiffness can promote dentinogenesis in odontoblast-like cells through a LAMB1–FAK–MEK1/2 mechanotransduction axis. Its combination of tunable PDMS substrates, mineralization assays, gene-expression analysis, and protein-interaction studies provides a framework for linking material mechanics to reparative dentin formation.